The year's first software IPO, Varonis Systems (VRNS), gained 100% on the first day of trading after pricing 22% above the midpoint of the original range. It marked the third IPO this year to have a 100% or greater first-day return after Dicerna (DRNA) and...read more
Lumenis, which sells laser-based systems used in surgical, ophthalmic and aesthetic procedures, raised $75 million by offering 6.3 million shares at $12, well below the range of $15 to $17. Lumenis will list on the NASDAQ under the symbol LMNS. Goldman Sachs,...read more
Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more
US IPO Recap: Varonis provides data security for enterprises and financial security for investors
The year's first software IPO, Varonis Systems (VRNS), gained 100% on the first day of trading after pricing 22% above the midpoint of the original range. It marked the third IPO this year to have a 100% or greater first-day return after Dicerna (DRNA) and...read more
Lumenis prices IPO at $12, well below the range
Lumenis, which sells laser-based systems used in surgical, ophthalmic and aesthetic procedures, raised $75 million by offering 6.3 million shares at $12, well below the range of $15 to $17. Lumenis will list on the NASDAQ under the symbol LMNS. Goldman Sachs,...read more
2 US IPOs planned for the week of Feb 24
The following IPOs are expected to price this week: Lumenis (LMNS), which sells laser-based systems used in surgical, ophthalmic and aesthetic procedures, plans to raise...read more
US IPO Recap: Wave goodbye to the biotech wave as tech prepares to take over
Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more